These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2500273)

  • 1. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.
    Garbett ND; Currie DC; Cole PJ
    Clin Exp Immunol; 1989 Apr; 76(1):1-7. PubMed ID: 2500273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose intravenous immunoglobulin therapy in burn patients: pharmacokinetics and effects on microbial opsonization and phagocytosis.
    Hansbrough JF; Miller LM; Field TO; Gadd MA
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S49-56. PubMed ID: 3041358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anaphylactic shock reaction following intravenous administration of 7S immunoglobulin in patients with hypogammaglobulinemia, especially in children with acute lymphoblastic leukemia (ALL)].
    Manzke H; Seifert J
    Klin Padiatr; 1987; 199(4):274-8. PubMed ID: 3116320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of treatment of children with hypogammaglobulinemia: comparison of fresh plasma and intravenous immunoglobulin preparation.
    Bernatowska E; Weremowicz R; Janowicz W; Madaliński K
    Arch Immunol Ther Exp (Warsz); 1986; 34(4):377-84. PubMed ID: 3099724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunoglobulin replacement therapy contribution in agammaglobulinemia: 10 case reports].
    Ksouri H; Mellouli F; Barbouch R; Ben Hassen A; Béjaoui M
    Arch Pediatr; 2006 Jul; 13(7):1034-9. PubMed ID: 16713207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia.
    Roifman CM; Gelfand EW
    Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S92-6. PubMed ID: 3399285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J; Lokaj J; Stikarovská D; Mayer J; Thon V; Eibl MM
    Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
    Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
    Pirofsky B
    Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of Triethanolamine (CAS No. 102-71-6) in F344 Rats and B6C3F1 Mice (Dermal Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Nov; 449():1-298. PubMed ID: 12594526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tolerability and pharmacokinetics of an intravenous immunoglobulin preparation in immunologically normal subjects and tolerability in patients with hypogammaglobulinemia resulting from chronic lymphatic leukemia].
    Huser HJ; Schwander D; Wegmann A; Chariatte N; Fässler MA
    Schweiz Med Wochenschr; 1986 Feb; 116(5):151-6. PubMed ID: 3515530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of primary immunodeficiencies with intravenous gamma globulin].
    García Rodríguez C; López Trascasa M; Ferreira Cerdán A; Fontán Casariego G
    An Esp Pediatr; 1987 Dec; 27(6):411-5. PubMed ID: 2451892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin.
    Mondorf AW; Stephan W; Uthemann H; Schuppan D; Lissner R
    Arzneimittelforschung; 1981; 31(11):1928-30. PubMed ID: 6797445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB; Hanna K;
    Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.